Advisor Group’s CytomX Therapeutics CTMX Stock Holding History

Advisor Group’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-100	Closed	-$1K	–	5247
2019 Q1	$1K	Hold	100	–	–	﹤0.01%	5044
2018 Q4	$2K	Buy	+100	New	+$1.48K	﹤0.01%	4803

Other funds holding CTMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Advisor Group's CTMX Position: Q2 2019 in Review

Advisor Group sold out of CytomX Therapeutics (CTMX) in Q2 2019, closing a stake of 100 shares — an estimated $1K sold.

Advisor Group first reported a position in CTMX in Q4 2018 and held it in 2 quarters. The position peaked at $2K in Q4 2018. 109 funds tracked by Wall St. Rank hold CTMX as of Q2 2019.

Advisor Group reported no remaining CytomX Therapeutics position as of Q2 2019 after selling out during the quarter.
Advisor Group sold 100 CytomX Therapeutics shares in Q2 2019, an estimated $1K.
Advisor Group first reported a position in CytomX Therapeutics in Q4 2018 and held it in 2 quarters.
Advisor Group's CytomX Therapeutics position peaked at $2K in Q4 2018.
109 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2019.

Based on Advisor Group's 13F filing for Q2 2019, filed 31 Jul 2019.